Rossari Biotech Ltd Q2 FY2027 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/rdxfgel6ynwf33pun629bxo1.pdf

Key Takeaways


Topline & Profitability

Ketan Sablok: "Even though our exports have grown significantly, the freight costs have almost doubled, tripled over what they were in the first half of last year or Q2 of last year. That has significantly impacted our EBITDA margins."

Export & International Expansion


New Initiatives & Product Pipeline

Sunil Chari: "So once you get it to the customer, the customer does not throw you out fast. Price and all are not the key criteria for changeover in a pharma kind of excipient."

Institutional & B2C Business

Ketan Sablok: "We still are on that plan of moving out of this B2C business. We will do that, as we had said last time also, at an appropriate time and at an appropriate value. Till we reach that point, I think our aim is that we should still run this business on a positive note and that is what we are doing. But our overall plan still remains to move out of the non-core businesses that we have."

Raw Material & Supply Chain


Capital Allocation & Balance Sheet


Guidance & Commitments

CommitmentSpecificsTimeline
Export revenue shareAt least 30%+ of revenue from exportsBy end of FY27
Institutional/B2C profitabilityH2 FY27 EBITDA positive; full-year at least breakevenFY27
FY27 revenue growthMid-teen to high-teen percentage (raised from initial 12–14%)FY27
FY27 EBITDA marginAround 12% plus/minus for the full yearFY27
EBITDA margin improvementImprovements in EBITDA percentage expectedFrom next year (FY28)
Ethylene oxide supplyHoping no EO constraints; Reliance expansion expected to bring higher allocationQ3 FY27 (no constraint); Q1 FY28 (higher allocation)
Dahej ethoxylation utilizationHealthy utilization expected; peak utilization by end of FY28Q2–Q3 FY28 (healthy); FY28-end (peak)
Working capital debtPaid off, debt-free on that portionBy mid of next year
Net working capital daysRemain within 87–90 daysBy end-March FY27
ROCEUpward trajectory likelyNext year (FY28)
KSA project detailsBlueprint, financials, CAPEX, products to be shared with BoardSome developments over next 8–12 months

Key Metrics

MetricQ2 FY27
Revenue from operations₹697.6 cr, +19% YoY over ₹586.1 cr in Q2 FY26, highest-ever quarterly revenue
Gross margin31.6%, in line with Q2 FY26, +200 bps QoQ from 29.6% in Q1 FY27
EBITDA₹87 cr, +21% YoY, highest-ever quarterly EBITDA
EBITDA margin12.5%, vs 12.3% in Q2 FY26 and 11.6% in Q1 FY27, +91 bps QoQ
Profit after tax₹38.9 cr, +5.5% YoY and +11% QoQ
Diluted EPS₹7.02
Core B2B revenue₹619.9 cr, +21% YoY
Core B2B EBITDA margin14.1%, vs 14.8% in Q2 FY26 and 13.5% in Q1 FY27
Institutional and B2C revenue₹77.7 cr, +3% YoY
Institutional and B2C EBITDA₹0.2 cr positive, vs EBITDA loss of ₹3.7 cr in Q2 FY26
HPPC revenue₹541.9 cr, +18% YoY
Textile Speciality Chemicals revenue₹120.8 cr, +26% YoY, +~14% QoQ
Animal Health and Nutrition revenue₹34.8 cr, +11% YoY
Export contribution~31% of revenue, vs 27% in H1 FY27
Net debt₹221 cr, vs ₹248 cr in Jun '26 and ₹281 cr in Mar '26
Net debt-to-equity ratio0.16
Working capital days86 days, improved from 97 days at end of FY26
Blended capacity utilization~60%
New ethoxylation facility utilization~30%, ramping up